On the other hand, we think 2023 sets up as a difficult U.S. budget environment, with significant downside potential if tensions ease." Bank of America reiterates Bristol-Myers Squibb as buy Bank of America called the pharmaceutical company a "deep value stock." "In a rising rate environment where investors are more focused on defensive names and cash flow, we continue to view BMY shares as attractive."